Concurrent suppression of Aβ aggregation and NLRP3 inflammasome activation for treating Alzheimer's disease-Reference-Cited by-全球学者库

Concurrent suppression of Aβ aggregation and NLRP3 inflammasome activation for treating Alzheimer's disease

Published:2022 Issue:10 Volume:13 Page:2971-2980
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Yang Tao¹,Zhang Lei¹,Shang Yicun¹,Zhu Zhenzhu¹^ORCID,Jin Suxing²³^ORCID,Guo Zijian³^ORCID,Wang Xiaoyong¹^ORCID

Affiliation:

1. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, P. R. China

2. School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing 210023, P. R. China

3. State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, P. R. China

Abstract

Bifunctional molecule BPBA inhibits Aβ aggregation and NLRP3 inflammasome activation, thereby decreasing ROS and IL-1β in vitro and vivo; it synergistically prevents Alzheimer's disease via alleviating Aβ neurotoxicity and reducing neuroinflammation.

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/SC/D1SC06071F

Reference63 articles.

1. Alzheimer’s Association Report , 2020, Alzheimer's Disease Facts and Figures, Alzheimer's Dement , 2020 , 16 , pp. 391–460

2. Alzheimer’s Disease International , 2019 , World Alzheimer Report 2019: Attitudes to dementia , Alzheimer’s Disease International , London